SpyGlassPharma
ALISO VIEJO, California, United States · Biotechnology, Healthcare, Health Care
SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.
Key facts
- Headquarters
- ALISO VIEJO, California, United States
- Employees
- 40
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (SGP)
- Website
- spyglassophthalmics.com
- Company page
Recent activity at SpyGlassPharma
- : SEC 8-K (8.01): On October 19, 2026, SpyGlass Pharma, Inc. announced positive interim 4-year data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, highlighting significant progress in their clinical study. The press release, attached as Exhibit 99.1, underscores the implications of this data for the company's drug development pipeline and potential market impact. This announcement may enhance investor confidence and affect the company's stock performance positively. The data pertains directly to the ongoing clinical updates, which are critical for stakeholders in the biotech industry.
- : SpyGlass Pharma, Inc. Acquires Santen Holdings US, Inc.
- : SEC 8-K (8.01): On October 1, 2026, SpyGlass Pharma, Inc. completed a Stock Purchase Agreement with Santen Holdings US, Inc., involving the acquisition of certain assets. Details on the financial implications of this acquisition, including purchase prices or amounts, were not fully disclosed. This acquisition is strategically significant as it may enhance SpyGlass Pharma’s market position in the pharmaceutical industry. The agreement could also facilitate potential growth opportunities in product offerings or research advancements. The effective date of the agreement is explicitly stated as October 1, 2026.
- : SEC 8-K (8.01): On March 9, 2026, SpyGlass Pharma, Inc. issued a press release detailing positive top-line 12-month clinical updates from their Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System. This development could have significant implications for the company's future product offerings and market position in ophthalmic devices. The updates are crucial for stakeholders and may influence investor confidence in the company's growth prospects. The press release serves to inform security holders about these important clinical trial results.
- : SEC 8-K (8.01): On March 9, 2026, SpyGlass Pharma, Inc. issued a press release announcing positive top-line 12-month clinical updates for its Bimatoprost Drug Pad-IOL System, which is currently being evaluated in a Phase 1/2 trial. This update signifies a critical advancement in the clinical trial process, potentially leading to further development stages. The press release is intended to inform stakeholders about the progress and outcomes related to this innovative therapeutic system. No financial amounts were mentioned, but the implications of successful trial results could significantly impact SpyGlass Pharma's market position and future funding opportunities.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On February 5, 2026, Habib Dable was appointed to the board of directors of SpyGlass Pharma, Inc. in connection with the Company's initial public offering. He will serve as a Class I director and member of the compensation committee, replacing no prior director. Mr. Dable has a substantial background in the biopharmaceutical sector, having previously served as President and CEO of Acceleron Pharma until its acquisition by Merck in November 2021. No arrangements were disclosed regarding his election, and an indemnification agreement was executed on the same date, aligning with standard corporate practices. Additionally, Mr. Dable will receive a base annual retainer of $40,000, further indicating the Company’s commitment to attracting experienced professionals to its board during this critical growth phase.
- : SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer
- : SpyGlassPharma
- : SpyGlass Pharma has raised $75 million in a Series D funding round led by Sands Capital to further its Drug Delivery Platform for glaucoma patients.
SpyGlassPharma funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2025 | Venture | $75.0M |
| Jun 2025 | Series D | $75.0M |
| Jul 2023 | Venture | $40.0M |
| Jan 2021 | Venture | $13.7M |
| Jun 2019 | Venture | $6.0M |
Leadership
- Glenn Sussman, Co-Founder and CTO
- Glenn Sussman, Executive Officer, Director
- Malik Kahook, Executive Officer, Director
- Ali Behbahani, Director
- Tak Cheung, Director
- Kirk Nielsen, Director
- Cynthia Yee, Director
- Ali Behbahani, Director
- Malik Kahook, Executive Officer, Director
- Glenn Sussman, Executive Officer, Director
- Rachel Gillette, Vice President, Human Resources
- Jean-Frédéric Viret, Chief Financial Officer
Verified email and direct lines for SpyGlassPharma’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Companies similar to SpyGlassPharma
- ImmersiveTouch · Biotechnology, Healthcare, Health Care
- ETON PHARMACEUTICALS · Biotechnology, Healthcare, Health Care
- MiCare Path · Biotechnology, Healthcare, Health Care
- Vektor Medical · Biotechnology, Healthcare, Health Care
- NOWDiagnostics, Inc. · Biotechnology, Healthcare, Health Care
About SpyGlassPharma: questions and answers
What does SpyGlassPharma do?
SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.
Where is SpyGlassPharma headquartered?
SpyGlassPharma is headquartered in ALISO VIEJO, California, United States.
How many employees does SpyGlassPharma have?
SpyGlassPharma has about 40 employees.
Has SpyGlassPharma raised funding?
Yes. Fundz has recorded 5 funding events for SpyGlassPharma. The most recent, $75.0M, was in Jun 2025.
Who leads SpyGlassPharma?
Glenn Sussman is a Co-Founder and CTO at SpyGlassPharma.
What is the latest news on SpyGlassPharma?
On Oct 19, 2026, SEC 8-K (8.01): On October 19, 2026, SpyGlass Pharma, Inc. announced positive interim 4-year data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, highlighting significant progress in their clinical study. The press release, attached as Exhibit 99.1, underscores the implications
Is SpyGlassPharma a public company?
Yes. SpyGlassPharma is publicly traded under the ticker SGP.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy